294 related articles for article (PubMed ID: 24393433)
1. Effect of Renin-Angiotensin system inhibition on cardiovascular events in older hypertensive patients with metabolic syndrome.
Zreikat HH; Harpe SE; Slattum PW; Mays DP; Essah PA; Cheang KI
Metabolism; 2014 Mar; 63(3):392-9. PubMed ID: 24393433
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
Lee J; Lee S
Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
[TBL] [Abstract][Full Text] [Related]
3. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast Growth Factor-23, Heart Failure Risk, and Renin-Angiotensin-Aldosterone-System Blockade in Hypertension: The MESA Study.
Akhabue E; Vu TT; Vaidya A; Michos ED; de Boer IH; Kestenbaum B; Allison M; Szklo M; Ouyang P; Yancy CW; Wolf M; Isakova T; Carnethon MR
Am J Hypertens; 2019 Jan; 32(1):18-25. PubMed ID: 30256890
[TBL] [Abstract][Full Text] [Related]
5. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.
Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q
J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513
[TBL] [Abstract][Full Text] [Related]
6. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
Zhang P; Zhu L; Cai J; Lei F; Qin JJ; Xie J; Liu YM; Zhao YC; Huang X; Lin L; Xia M; Chen MM; Cheng X; Zhang X; Guo D; Peng Y; Ji YX; Chen J; She ZG; Wang Y; Xu Q; Tan R; Wang H; Lin J; Luo P; Fu S; Cai H; Ye P; Xiao B; Mao W; Liu L; Yan Y; Liu M; Chen M; Zhang XJ; Wang X; Touyz RM; Xia J; Zhang BH; Huang X; Yuan Y; Loomba R; Liu PP; Li H
Circ Res; 2020 Jun; 126(12):1671-1681. PubMed ID: 32302265
[TBL] [Abstract][Full Text] [Related]
7. Renin-angiotensin-aldosterone system inhibitors and SARS-CoV-2 infection: an analysis from the veteran's affairs healthcare system.
Sandhu AT; Kohsaka S; Lin S; Woo CY; Goldstein MK; Heidenreich PA
Am Heart J; 2021 Oct; 240():46-57. PubMed ID: 34126079
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors on cardiovascular outcomes in patients initiating peritoneal dialysis.
Shen JI; Saxena AB; Montez-Rath ME; Leng L; Chang TI; Winkelmayer WC
J Nephrol; 2017 Apr; 30(2):281-288. PubMed ID: 27485007
[TBL] [Abstract][Full Text] [Related]
9. Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study.
Bauer AZ; Gore R; Sama SR; Rosiello R; Garber L; Sundaresan D; McDonald A; Arruda P; Kriebel D
J Clin Hypertens (Greenwich); 2021 Jan; 23(1):21-27. PubMed ID: 33220171
[TBL] [Abstract][Full Text] [Related]
10. RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies.
COVID-19 RISk and Treatments (CORIST) Collaboration
Vascul Pharmacol; 2020 Dec; 135():106805. PubMed ID: 32992048
[TBL] [Abstract][Full Text] [Related]
11. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-Receptor Blocker, Angiotensin-Converting Enzyme Inhibitor, and Risks of Atrial Fibrillation: A Nationwide Cohort Study.
Hsieh YC; Hung CY; Li CH; Liao YC; Huang JL; Lin CH; Wu TJ
Medicine (Baltimore); 2016 May; 95(20):e3721. PubMed ID: 27196491
[TBL] [Abstract][Full Text] [Related]
13. Prescription of renin-angiotensin system blockers and risk of acute kidney injury: a population-based cohort study.
Mansfield KE; Nitsch D; Smeeth L; Bhaskaran K; Tomlinson LA
BMJ Open; 2016 Dec; 6(12):e012690. PubMed ID: 28003286
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular death in kidney recipients treated with renin-angiotensin system blockers.
Opelz G; Döhler B
Transplantation; 2014 Feb; 97(3):310-5. PubMed ID: 24492421
[TBL] [Abstract][Full Text] [Related]
15. Impact of Angiotensin II Signaling Blockade on Clinical Outcomes in Patients with Inflammatory Bowel Disease.
Jacobs JD; Wagner T; Gulotta G; Liao C; Li YC; Bissonnette M; Pekow J
Dig Dis Sci; 2019 Jul; 64(7):1938-1944. PubMed ID: 30725290
[TBL] [Abstract][Full Text] [Related]
16. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis.
Vejakama P; Thakkinstian A; Lertrattananon D; Ingsathit A; Ngarmukos C; Attia J
Diabetologia; 2012 Mar; 55(3):566-78. PubMed ID: 22189484
[TBL] [Abstract][Full Text] [Related]
17. Influence of Renin-Angiotensin System Inhibitors on Lower-Respiratory Tract Infections in Type 2 Diabetes: The Fremantle Diabetes Study Phase II.
Davis TME; Davis WA
Diabetes Care; 2020 Sep; 43(9):2113-2120. PubMed ID: 32616610
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers (ACEI/ARB) are Associated with Improved Limb Salvage after Infrapopliteal Interventions for Critical Limb Ischemia.
Khan SZ; Montross B; Rivero M; Cherr GS; Harris LM; Dryjski ML; Dosluoglu HH
Ann Vasc Surg; 2020 Feb; 63():275-286. PubMed ID: 31626938
[TBL] [Abstract][Full Text] [Related]
19. Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study.
Zhong Y; Zhao L; Wu G; Hu C; Wu C; Xu M; Dong H; Zhang Q; Wang G; Yu B; Lv J; Wu C; Zhang S; Cao C; Shu L; Pan Y; Liu X; Wu F
J Int Med Res; 2020 Dec; 48(12):300060520979151. PubMed ID: 33322988
[TBL] [Abstract][Full Text] [Related]
20. Impact of renin-angiotensin-aldosterone system inhibition on mortality in critically ill COVID-19 patients with pre-existing hypertension: a prospective cohort study.
Sato K; White N; Fanning JP; Obonyo N; Yamashita MH; Appadurai V; Ciullo A; May M; Worku ET; Helms L; Ohshimo S; Juzar DA; Suen JY; Bassi GL; Fraser JF; Arora RC;
BMC Cardiovasc Disord; 2022 Mar; 22(1):123. PubMed ID: 35321649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
